Raffaele Bruno

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. ncbi request reprint Prevalence and histologic features of transfusion transmitted virus and hepatitis C virus coinfection in a group of HIV patients
    R Bruno
    Division of Infectious and Tropical Diseases, University of Pavia, IRCCS S Matteo, Pavia, Italy
    Dig Liver Dis 32:617-20. 2000
  2. ncbi request reprint Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review
    R Bruno
    Division of Infectious and Tropical Disease, IRCCS S Matteo Hospital, University of Pavia, 27100 Pavia, Italy
    Dig Liver Dis 38:363-73. 2006
  3. ncbi request reprint Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Instituto di Ricerca e Cura a Carattere Scientifico, San Matteo Hospital, University of Pavia, Italy
    J Acquir Immune Defic Syndr 46:297-303. 2007
  4. pmc Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C
    Raffaele Bruno
    Division of Infectious and Tropical Disease IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    BMC Infect Dis 2:17. 2002
  5. ncbi request reprint Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study
    R Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    Aliment Pharmacol Ther 26:369-76. 2007
  6. ncbi request reprint Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    J Hepatol 44:S146-50. 2006
  7. ncbi request reprint Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, Pavia, Italy
    AIDS 17:S83-7. 2003
  8. ncbi request reprint Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    Antivir Ther 10:201-5. 2005
  9. ncbi request reprint Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    Antivir Ther 9:491-7. 2004
  10. ncbi request reprint Pathogenesis of liver damage in HCV-HIV patients
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    AIDS Rev 10:15-24. 2008

Detail Information

Publications52

  1. ncbi request reprint Prevalence and histologic features of transfusion transmitted virus and hepatitis C virus coinfection in a group of HIV patients
    R Bruno
    Division of Infectious and Tropical Diseases, University of Pavia, IRCCS S Matteo, Pavia, Italy
    Dig Liver Dis 32:617-20. 2000
    ..A recently identified DNA transfusion-transmitted virus has been associated with post-transfusion non-A to G hepatitis...
  2. ncbi request reprint Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review
    R Bruno
    Division of Infectious and Tropical Disease, IRCCS S Matteo Hospital, University of Pavia, 27100 Pavia, Italy
    Dig Liver Dis 38:363-73. 2006
    ....
  3. ncbi request reprint Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Instituto di Ricerca e Cura a Carattere Scientifico, San Matteo Hospital, University of Pavia, Italy
    J Acquir Immune Defic Syndr 46:297-303. 2007
    ..This study was designed to investigate the incidence and type of liver-related complications and mortality in coinfected cirrhotic patients...
  4. pmc Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C
    Raffaele Bruno
    Division of Infectious and Tropical Disease IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    BMC Infect Dis 2:17. 2002
    ..In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule...
  5. ncbi request reprint Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study
    R Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    Aliment Pharmacol Ther 26:369-76. 2007
    ..Peginterferon alpha-2a and alpha-2b, the two commercially available pegylated interferons, have different pharmacokinetic properties that produce differing abilities to suppress replication of the hepatitis C virus...
  6. ncbi request reprint Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    J Hepatol 44:S146-50. 2006
    ..Prevention of hepatitis and cirrhosis are key goals in reducing the impact of HCC. Numerous issues in HCC prevention, diagnosis, and management still remain to be resolved through large-scale, randomized clinical trials...
  7. ncbi request reprint Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, Pavia, Italy
    AIDS 17:S83-7. 2003
    ..This finding points out the need of improving our knowledge about the pathogenesis, diagnosis and treatment of this kind of complication...
  8. ncbi request reprint Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    Antivir Ther 10:201-5. 2005
    ..8%). Thus, there appears to be no rationale for a body-weight dosing regimen for peginterferon alpha-2a, and such dosing does not achieve more consistent AUC measurements in patients receiving peginterferon alpha-2b...
  9. ncbi request reprint Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    Antivir Ther 9:491-7. 2004
    ..Larger-scale studies assessing both viral kinetics and sustained virological responses are needed to confirm these observations...
  10. ncbi request reprint Pathogenesis of liver damage in HCV-HIV patients
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    AIDS Rev 10:15-24. 2008
    ....
  11. ncbi request reprint Management of hepatitis C in human immunodeficiency virus-infected patients
    R Bruno
    Division of Infectious and Tropical Diseases, IRCCS S Matteo Hospital, University of Pavia, Italy
    Dig Liver Dis 34:452-9. 2002
    ..Since management of co-infected patients is complex a multidisciplinary approach is needed in order to facilitate care and help patients to achieve a positive outcome...
  12. doi request reprint Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Foundation IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
    Dig Liver Dis 43:575-8. 2011
    ..Aims of this study were to analyse the association of two non-invasive liver fibrosis evaluation methods, liver stiffness measurement and FIB4, and their correlation with metabolic parameters...
  13. ncbi request reprint Challenges for hepatitis C patients coinfected with HIV
    Raffaele Bruno
    Hepatology Outpatients Unit, IRCCS S Matteo Hospital University of Pavia, Via Taramelli 5, 27100 Pavia, Italy
    Am Clin Lab 21:26-31. 2002
  14. ncbi request reprint Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV
    R Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Italy
    Clin Pharmacokinet 40:695-700. 2001
    ..To compare the plasma pharmacokinetics of lamivudine 150mg twice daily and 300mg once daily in patients with HIV-1 infection...
  15. ncbi request reprint Host factors affecting the outcome of treatment of hepatitis C
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital University of Pavia, Pavia, Italy
    Rev Gastroenterol Disord 4:S3-7. 2004
    ..Results of a head-to-head comparison have demonstrated the possibility that, in cases of dose reduction, levels of peginterferon alfa-2a could remain above the limit of detection, whereas those of peginterferon alfa-2b might not...
  16. ncbi request reprint HCV chronic hepatitis in patients with HIV: clinical management issues
    Raffaele Bruno
    Division of Infectious and Tropical Disease, IRCCS S Matteo Hospital, University of Pavia, Italy
    Am J Gastroenterol 97:1598-606. 2002
    ..Liver transplantation in HIV patients is currently under evaluation, but should become the rescue therapy for HIV patients with end stage liver disease...
  17. ncbi request reprint Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients
    Eleng Seminari
    Infectious Disease Department, IRCCS, Policlinico S Matteo Hospital, University of Pavia, Pavia, Italy
    Antivir Ther 7:175-80. 2002
    ..Patients with lipoatrophy had had a greater exposure to stavudine...
  18. ncbi request reprint Hepatotoxicity and nelfinavir: a meta-analysis
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Mateo Hospital University of Pavia, Italy
    Clin Gastroenterol Hepatol 3:482-8. 2005
    ..The aim of this study was to identify the relative potential for developing hepatotoxicity for nelfinavir vs other protease inhibitors...
  19. pmc Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus and treated with antiretroviral drugs
    Milena Furione
    Servizio di Virologia, Laboratori di Ricerca, Area Infettivologica, IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Via Taramelli 5, 27100 Pavia, Italy
    J Clin Microbiol 42:3012-6. 2004
    ....
  20. pmc Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
    Stefania Paolucci
    Molecular Virology Unit, Virology and Microbiology Department, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Virol J 10:355. 2013
    ..The aim of this study was to illustrate potential natural DAA-resistance mutations in the HCV NS5A and NS5B regions of HCV genotypes 1a and 1b from DAA-naïve patients...
  21. ncbi request reprint Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis
    Enrico Brunetti
    Division of Infectious and Tropical Diseases, IRCSS S Matteo, University of Pavia, Via Taramelli 5, 27100 Pavia, Italy
    J Hepatol 40:501-6. 2004
    ..As fine needles (FN) do not require anaesthesia, are used over a wider range of coagulation values and allow multiple passes, we compared the diagnostic yield of FN vs. CN biopsies...
  22. doi request reprint Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C
    Raffaele Bruno
    Department of Infectious Diseases, Foundation IRCCS San Matteo Hospital University of Pavia, Pavia, Italy
    Dig Liver Dis 43:337-44. 2011
    ..The lesson of HIV therapy, provide a compelling case for the exploration of combinations of direct-acting antiviral agents...
  23. ncbi request reprint Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas
    Luca Arcaini
    Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
    Curr Clin Pharmacol 5:74-81. 2010
    ....
  24. ncbi request reprint Distinct mutational drug resistance profiles of HIV-1 RNA in plasma and culture isolates of patients receiving antiretroviral therapy
    Marizia Debiaggi
    Department of Microbiology, University of Pavia School of Medicine and IRCCS Policlinico San Matteo, Pavia, Italy
    Intervirology 45:52-5. 2002
    ..These results emphasize the need for standardization and clinical laboratory use of phenotypic assays that avoid extensive cocultivation...
  25. doi request reprint gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis
    Raffaele Bruno
    Division of Infectious and Tropical Diseases, University of Pavia Foundation, IRCCS, San Matteo Hospital, Pavia, Italy
    Gut 59:513-20. 2010
    ..In this study, an investigation was carried out to determine whether gp120, an HIV envelope protein, modulates the biology of human hepatic stellate cells (HSCs), key cell types in the pathogenesis of fibrosis...
  26. ncbi request reprint Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT
    M Paulli
    Department of Human Pathology, University of Pavia, Pavia, Italy
    Ann Oncol 21:1189-95. 2010
    ..Marginal zone B-cell lymphoma (MZL) represents one of the most frequent lymphoma subtypes associated with HCV infection. We describe an unusual subset of HCV-associated MZL characterized by subcutaneous presentation...
  27. ncbi request reprint Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy
    M Debiaggi
    Department of Microbiology, University of Pavia, IRCCS Policlinico San Matteo, via Brambilla, 74 27100, Pavia, Italy
    Int J Infect Dis 4:187-93. 2000
    ..To assess the prognostic role of proviral DNA in peripheral blood mononuclear cells (PBMC) of patients with undetectable viremia over long-term highly active antiretroviral therapy (HAART)...
  28. doi request reprint Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas
    Luca Arcaini
    Divison of Hematology, Fondazione IRCCS Policlinico S Matteo, University of Pavia, Viale Golgi 19, Pavia, Italy
    Am J Hematol 85:46-50. 2010
    ..This could be a limit to the application of immunochemotherapy programs. HCV+ lymphomas represent a distinct clinical subset of NHL that deserves specific clinical approach to limit liver toxicity and ameliorate survival...
  29. ncbi request reprint Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy
    M Debiaggi
    Department of Microbiology, University of Pavia, Italy
    Eur J Clin Microbiol Infect Dis 20:91-6. 2001
    ....
  30. pmc Forecast model for the evaluation of economic resources employed in the health care of patients with HIV infection
    Paolo Sacchi
    Divisione di Malattie Infettive e Tropicali Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Clinicoecon Outcomes Res 4:117-26. 2012
    ..The aim of the present study is to define a pharmacoeconomic model for the forecast of the costs of a group of chronically treated patients followed over the period 2004-2009...
  31. ncbi request reprint Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT
    L Arcaini
    Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
    Ann Oncol 18:346-50. 2007
    ....
  32. ncbi request reprint Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients
    Jacob Nattermann
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Hepatology 46:1016-25. 2007
    ..1; P = 0.004). This effect corresponds to the in vitro observation that in HCV core-transfected HUH7 cells, IL-6 overcomes the HCV core-mediated inhibition of STAT3 activation...
  33. ncbi request reprint Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier García-Samaniego
    Massimo Puoti
    Department of Infectious Diseases, University of Brescia AO Spedali Civili, Brescia, Italy
    HIV Clin Trials 3:419-20. 2002
  34. ncbi request reprint Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali Università degli Studi di Brescia AO Spedali Civili, Brescia, Italy
    HIV Clin Trials 3:324-32. 2002
    ..The search for the perfect treatment continues...
  35. ncbi request reprint Prevalence of metabolic syndrome among HIV patients
    Carmine Gazzaruso
    Diabetes Care 25:1253-4. 2002
  36. ncbi request reprint Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects
    Massimo Puoti
    Clinica di Malattie Infecttive e Tropicali, Università degli studi de Brescia, AO Spedali Civili dei Brescia
    AIDS Rev 4:27-35. 2002
    ..Highly Active Anti-Hepatitis B Therapy will probably soon come of age...
  37. ncbi request reprint Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a
    Giulia Morsica
    AIDS 18:1080-2. 2004
  38. ncbi request reprint Mitochondrial toxicity in HIV-HCV coinfection: It depends on the choice of antiretroviral drugs?
    Raffaele Bruno
    Hepatology 35:500-1. 2002
  39. ncbi request reprint Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop
    Giampiero Carosi
    Department of Infectious Disease, University of Brescia, Brescia, Italy
    AIDS Rev 7:161-7. 2005
    ....
  40. ncbi request reprint The pavia consensus statement
    Paul A Volberding
    University of California, San Francisco, USA
    AIDS 17:S170-9. 2003
  41. ncbi request reprint Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome
    Massimo Puoti
    FClinica di Malattie Infettive, Università degli Studi di Brescia AO Spedali Civili, Brescia, Clinica di Malattie Infettive e Tropicali, Madrid, Spain
    AIDS 18:2285-93. 2004
    ..Hepatocellular carcinoma (HCC) is an increasing cause of mortality in HIV-seropositive individuals. The aim of the study was to compare the main features of HCC in HIV-seropositive individuals with those in to HIV-negative patients...
  42. ncbi request reprint The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
    Massimo Puoti
    Institute of Infectious and Tropical Diseases, Spedali Civili, University of Brescia, Brescia, Italy
    Antivir Ther 9:811-7. 2004
    ..3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen...
  43. ncbi request reprint Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo
    Raffaele Bruno
    AIDS 17:2674-5. 2003
  44. ncbi request reprint Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue
    Raffaele Bruno
    J Acquir Immune Defic Syndr 30:535-6. 2002
  45. ncbi request reprint High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk
    Raffaele Bruno
    J Acquir Immune Defic Syndr 31:363-5. 2002
  46. ncbi request reprint Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection
    Guenther Schmutz
    Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
    AIDS 20:1951-4. 2006
    ..It is unknown to date whether combination therapy with lamivudine plus tenofovir could be superior to sequential therapy with tenofovir after the occurrence of lamivudine resistance...
  47. ncbi request reprint Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy
    Raffaele Bruno
    AIDS 17:783-4. 2003
  48. ncbi request reprint Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome
    Carmine Gazzaruso
    Internal Medicine Unit, Cardiovascular Prevention Clinic ASTRA, IRCCS Maugeri Foundation Hospital, Scientific Institute of Pavia, Italy
    J Hypertens 21:1377-82. 2003
    ....
  49. ncbi request reprint Natural history of chronic hepatitis B in co-infected patients
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali, AO Spedali Civili, Universita di Brescia, P zzle Spedali Civili 1, I 25123 Brescia, Italy
    J Hepatol 44:S65-70. 2006
    ....
  50. ncbi request reprint Hepatitis B virus genotype distribution in HIV-1 coinfected patients
    Gianguglielmo Zehender
    Gastroenterology 125:1559-60; author reply 1660. 2003
  51. ncbi request reprint Comments on the review 'Care of patients with hepatitis C and HIV co-infection' by Soriano et al
    Raffaele Bruno
    AIDS 18:2101-2; author reply 2102-3. 2004
  52. ncbi request reprint Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?
    Raffaele Bruno
    J Acquir Immune Defic Syndr 45:123. 2007